Over the last few decades, the N-methyl-D-aspartate receptor (also known as the NMDA receptor or NMDAR) has received much attention due to their role in brain development and function. They are ionotropic receptors found in nerve cells, gets activated by binding of glutamate and glycine. NMDRs are heteromers composed of NR1 and NR2 subunits. NR2 subunits have four subtypes (A-D) in which NR2A and NR2B are predominant. NMDARs are critical to synaptic transmission, synaptic plasticity and memory function. Dysfunction in NMDAR causes several neuropathological and neurodegenerative disorders including schizophrenia, depression, tinnitus, epilepsy, neuropathic pain, Alzheimer’s disease, Huntington’s, Parkinson’s etc.
The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential clinically relevant therapeutics that aims at blocking excessive NMDA activation without interfering normal NMDA functionality required for normal synaptic transmission and plasticity. To date, several drugs has been developed and tested in different clinical studies and few have achieved FDA approval. Ketamine, methadone, memantine, amantadine, and dextromethorphan are the approved NMDAR antagonist. Amongst them, Ketamine is the strong NMDAR antagonist. Despite their clinical success, these drugs pose many side effects including hallucinations, catatonia, ataxia, nightmares, and memory deficits. These drugs are also addictive that makes it difficult to use for anything that requires prolonged dosing.
Over the time, researchers and drug developers are trying to overcome these side effects. Several emerging therapeutics are in late stage development that promise to provide maximum efficacy with minimum side effects. More than 20 companies are developing drug candidates against this potential target. The major players are Johnson & Johnson (esketamine), Auris Medical (Keyzilen), NeuroRx, Inc. (Cyclurad), Avanir Pharmaceuticals (CERC 301), etc., whose drugs are in late stage of clinical development.
Jyoti Kumari
Associate Analyst
It’s awesome to pay a quick visit this web page and reading the views
of all mates concerning this post, while I am also keen of getting know-how.
I am truly thankful to the holder of this web page who has shared this enormous piece of writing at at this time.
THANKYOU!!!
Amazing! Its genuinely awesome piece of writing, I have got much clear idea on the topic
of from this paragraph.
Hey There. I found your blog using msn. This is an extremely well written article.
I’ll be sure to bookmark it and return to read more of
your useful information. Thanks for the post. I will certainly return.
Hurrah! In the еnd I ցot a website frοm where
I be capable of genuinely ɡet valuable faϲts regarding my study andd knowledge.
Fоr most սp-to-date infߋrmation ʏoս hɑve to visit the web ɑnd οn web I foᥙnd tһіs site as ɑ best website for latest updates.
Saved as a favorite, I really like your site!